Your browser doesn't support javascript.
loading
Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia.
Bradstock, Kenneth F; Morley, Alec; Byth, Karen; Szer, Jeff; Prosser, Ian; Cannell, Paul; Irving, Ian; Seymour, John F.
Afiliação
  • Bradstock KF; Department of Haematology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Morley A; Flinders University and Medical Centre, Adelaide, South Australia, Australia.
  • Byth K; Research and Education Network, Westmead Hospital, Sydney, New South Wales, Australia.
  • Szer J; Royal Melbourne Hospital and University of Melbourne, Victoria, Australia.
  • Prosser I; Canberra Hospital, Australian Capital Territory, Australia.
  • Cannell P; Royal Perth Hospital, Perth, Western Australia, Australia.
  • Irving I; Department of Haematology, Townsville Hospital, Queensland, Australia.
  • Seymour JF; Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia.
Contemp Clin Trials Commun ; 4: 9-13, 2016 Dec 15.
Article em En | MEDLINE | ID: mdl-29736466
ABSTRACT
An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3-4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were comparable with those previously observed using a modified pediatric protocol. Overall survival at 5 years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL protocols, without improving long-term outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline Idioma: En Revista: Contemp Clin Trials Commun Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline Idioma: En Revista: Contemp Clin Trials Commun Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália